ARMP ▲ +6.5% - Armata Pharmaceuticals, Inc. $ARMP ARMP ARMP - Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 Armata Pharmaceuticals rose 6.5% after announcing that its AP-SA02 candidate received U.S. FDA Breakthrough Therapy Designation, a regulatory status that accelerates development and review timelines for drugs addressing serious conditions where preliminary evidence suggests substantial improvement over existing options. The designation typically signals FDA confidence in a drug's potential, which can reduce time to market and de-risk the development pathway for investors. 14-SEP-2026 07:01 AM ET